癌症（英文版）2013，Vol.32Issue(3)：136-140,5.DOI:10.5732/cjc.012.10160
The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations
The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations
Hidekazu Suzuki 1Tomonori Hirashima 1Norio Okamoto 1Tadahiro Yamadori 1Motohiro Tamiya 1Naoko Morishita 1Takayuki Shiroyama1
作者信息
- 1. Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, 3-7-1 Habikino,Habikino-shi, Osaka 583-8588, Japan
- 折叠
摘要
关键词
Tyrosine kinase inhibitor/ gefitinib/ erlotinib/ non-small cell lung cancer/epidermal growth factor receptor mutationKey words
Tyrosine kinase inhibitor/ gefitinib/ erlotinib/ non-small cell lung cancer/epidermal growth factor receptor mutation引用本文复制引用
Hidekazu Suzuki,Tomonori Hirashima,Norio Okamoto,Tadahiro Yamadori,Motohiro Tamiya,Naoko Morishita,Takayuki Shiroyama..The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations[J].癌症（英文版）,2013,32(3):136-140,5.
